SOMIT-CD Novel First-in-Class Specific Oromucosal Immunotherapy (SOMIT) to treat Celiac Disease (CD)
- Coordinator
- Allero Therapeutics BV, Netherlands
- Runs
- 1 September 2022 to 31 March 2025
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €3.6m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190104468
What the project is doing
In the project's own words, from its summary on CORDIS.
Celiac disease is an autoimmune indication for which there is no cure. Only the life-long avoidance of the disease causing gliadin protein in gluten is available as a sub-optimal and cumbersome necessity for CD patients. We developed a unique novel combination of antigen (gliadin protein), probiotic tolerogenic bacterial particles (TBPs) and mouth patch technology to enhance the bioavailability and tolerance induction.
Synergistic tolerizing properties of the TBP-antigen combination and the therapeutic effect of the SOMIT concept has been shown in a suitable pig model. Our SOMIT-CD promises to require a short-course weekly treatment for less than 3 months in CD patients. This EIC project will allow us to finalize the various preclinical activities and perform phase Ib/IIa clinical study, paving the way to closing a co-development deal with a big pharma player.
After market entry in 2029, we aim to reach a market share of 15% and generate annual revenues of 148M by 2033.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Allero Therapeutics BV | Rotterdam | Netherlands | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI